The Oncology Journal Club Episode 16

Pinterest LinkedIn Tumblr +

We’re back to our standard format for today’s episode of The Oncology Journal Club

This week the team are back with a standard format episode featuring their usual in-depth analysis and of course a little banter.

Hans Prenen gets us started with two papers on Selpercatinib and Eva talks us through next-generation sequencing for patients with metastatic cancers. Craig chats to us about estimated global cancer incidence in adults aged 80 or older and has a surprise dial in comment from Merve in New Zealand.

Quick Bites are back too – this week Eva covers a wide range of topics including Partial-Breast Irradiation, Metastatic Colorectal Cancer, Neuroendocrine Tumours and much more. We also have a quick PBS Update and Investor Update too so there’s a lot of detail packed into this 38 minutes.

With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!


About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.


This Week’s Papers:

  1. Drilon, Alexander, et al. Efficacy of Selpercatinib in RET Fusion–Positive NSCLC. August 27, 2020. N Engl J Med 2020; 383:813-824. DOI: 10.1056/NEJMoa2005653. Access online here.
  2. Wirth, Lori J., et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. August 27, 2020 N Engl J Med 2020; 383:825-835. DOI: 10.1056/NEJMoa2005651. Access online here.
  3. Mosele, F., et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. Published: August 24, 2020 DOI: https://doi.org/10.1016/j.annonc.2020.07.014. Access online here.
  4. Pilleron, Sophie, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Cancer Epidemiology. First published: 24 July 2020. https://doi.org/10.1002/ijc.33232

Quick Bites:

  1. Meattini, I., et al. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. Journal of Clinical Oncology. Published online August 24, 2020. Access online here.
  2. Singh, S., et al. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. Journal of Thoracic Oncology. July 11, 2020 DOI: Access online here.
  3. Cremolini, C.., et al. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.  Journal of Clinical Oncology. Published online August 20, 2020. Access online here.
  4. Castro, A., et al. Strength of immune selection in tumors varies with sex and age. Nat Commun 11,4128 (2020). Access online here.
  5. Nitecki R., et al. Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis [published online ahead of print, 2020 Jun 11]. JAMA Oncol. 2020;6(7):1-9. Access online here.

PBS Update:

Expanded access for KEYTRUDA ® (pembrolizumab)1 announced on fifth anniversary of immuno-oncology treatment on the PBS

Investor Update:

Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer


This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

 

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

 

 

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Merve AKA Christopher Jackson

MERVE… Chris Jackson

Chris Jackson is a Medical Oncologist with special interest in gastrointestinal cancers, melanoma and urological cancers. Chris holds a national role in the research and management of colorectal cancer.

Chris is currently the clinical leader for oncology research at Dunedin Hospital, and has strong links with cancer trials within New Zealand. In 2015 Chris was appointed as Medical Director of the Cancer Society of New Zealand.

Chris was born and raised in Otago and is strongly committed to the region. He is a cofounder of Mercy Cancer Care, with Mercy Hospital in 2011 ensuring that patients affected by cancer are offered a full range of systemic treatments that may not otherwise be available.

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Christopher Jackson and Graham Knowles.

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.